Versuchen GOLD - Frei

A high-stakes battle

Business Standard

|

July 11, 2025

The legal showdown between Sebi and Jane Street could redefine India's derivatives market

- KHUSHBOO TIWARI & SAMIE MODAK

A high-stakes battle

A legal battle is looming - one that could reshape India's derivatives market, the world's largest by trading volume, and set a precedent for how regulators worldwide draw the line between clever trading and market abuse.

The genesis of this battle lies in the sweeping crackdown the Securities and Exchange Board of India (Sebi) has launched against Jane Street, a USbased high-frequency trading (HFT) firm. Sebi has impounded ₹4,843 crore in alleged "unlawful gains", accusing Jane Street of orchestrating a sophisticated "sinister" scheme to manipulate the popular Bank Nifty index through aggressive derivative trading strategies.

Jane Street, a global titan in algorithmic trading, has fired back, calling Sebi's allegations "fundamentally mistaken". The firm is preparing to challenge the ban, likely at the Securities Appellate Tribunal.

The case, which could reach the Supreme Court, has ignited a fierce debate over what constitutes legitimate trading and what crosses into the realm of market manipulation.

With Indian retail investors suffering over ₹1 trillion in losses in 2024-25 (FY25), the stakes are monumentalnot just for Jane Street and Sebi, but also for the credibility and future of India's capital market ecosystem.

The anatomy of the allegations Sebi has laid out its case against Jane Street in a detailed, 105-page interim order, dated July 3, with voluminous annexures.

According to the regulator, the firm executed a two-pronged strategy: it aggressively bought Bank Nifty constituent stocks in both the cash and futures segments, artificially inflating the index. Later in the day, it offloaded those positions, while holding large short positions in index options, profiting from the index's decline.

WEITERE GESCHICHTEN VON Business Standard

Business Standard

Labour Codes impact: HCL tech profit slips 11%

Q3 top line beats Street estimates, bottom line misses expectations

time to read

2 mins

January 13, 2026

Business Standard

New labour Codes, restructuring weigh on TCS earnings

Tata Consultancy Services (TCS), India’s largest information technology (IT) services firm, saw its profit impacted in the October-December quarter by restructuring and changes in labour Codes.

time to read

1 min

January 13, 2026

Business Standard

Business Standard

Black drives the thrill for car buyers

Sees a surge in yearly sales, while white remains practical 'utility king'

time to read

2 mins

January 13, 2026

Business Standard

CHOOSING THE RIGHT B-SCHOOL TO MATCH YOUR CAREER GOALS

Success comes when you pick an institution that fits your professional dreams and your personality, helping you become the leader you want to be

time to read

2 mins

January 13, 2026

Business Standard

Business Standard

China’s PVC rethink to help India pipe makers

Supply likely to tighten after S-PVC rebate withdrawal

time to read

2 mins

January 13, 2026

Business Standard

Responsible growth

India must ensure data centres are sustainable

time to read

2 mins

January 13, 2026

Business Standard

India’s GenZ is full of creativity: PM

Prime Minister Narendra Modi on Monday said India's GenZ is full of creativity and with innovative ideas, energy and purpose, the country’s youth is at the forefront of nation-building.

time to read

1 min

January 13, 2026

Business Standard

Business Standard

Iran wants to negotiate after threats to attack, says Trump

At least 572 killed in protests; Tehran says situation ‘under full control’

time to read

2 mins

January 13, 2026

Business Standard

Insurers knock on Irdai door for clarity on director overlap ban

CLAUSE THREATENS BOARD STRUCTURES AT BANK-BACKED FIRMS SAYS INDUSTRY

time to read

2 mins

January 13, 2026

Business Standard

Delhi HC allows Zydus to sell generic version of cancer drug

Citing public interest, the Delhi High Court has cleared the way for Zydus Life-sciences to proceed with the sale of its version of the cancer drug nivolumab in India.

time to read

1 min

January 13, 2026

Listen

Translate

Share

-
+

Change font size